Insider Selling: Cardlytics, Inc. (NASDAQ:CDLX) Insider Sells 5,936 Shares of Stock

Cardlytics, Inc. (NASDAQ:CDLXGet Free Report) insider Nicholas Hollmeyer Lynton sold 5,936 shares of Cardlytics stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $3.08, for a total value of $18,282.88. Following the transaction, the insider now directly owns 85,445 shares in the company, valued at approximately $263,170.60. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Cardlytics Stock Performance

Shares of CDLX opened at $3.29 on Friday. The firm has a market cap of $160.50 million, a price-to-earnings ratio of -0.74 and a beta of 1.67. The company’s fifty day moving average is $4.24 and its 200-day moving average is $8.41. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 1.01. Cardlytics, Inc. has a 12 month low of $2.89 and a 12 month high of $20.52.

Cardlytics (NASDAQ:CDLXGet Free Report) last posted its earnings results on Wednesday, August 7th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.12. Cardlytics had a negative net margin of 50.21% and a negative return on equity of 17.96%. The firm had revenue of $69.64 million for the quarter, compared to the consensus estimate of $75.39 million. During the same period in the prior year, the business posted ($0.57) earnings per share. The business’s quarterly revenue was down 9.2% on a year-over-year basis. Equities analysts expect that Cardlytics, Inc. will post -1.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD boosted its position in Cardlytics by 6.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 29,769 shares of the company’s stock worth $432,000 after purchasing an additional 1,774 shares during the period. Canton Hathaway LLC boosted its position in shares of Cardlytics by 95.7% in the second quarter. Canton Hathaway LLC now owns 4,500 shares of the company’s stock valued at $37,000 after acquiring an additional 2,200 shares during the period. Susquehanna Fundamental Investments LLC boosted its position in shares of Cardlytics by 13.8% in the first quarter. Susquehanna Fundamental Investments LLC now owns 31,536 shares of the company’s stock valued at $457,000 after acquiring an additional 3,836 shares during the period. Quest Partners LLC boosted its position in shares of Cardlytics by 160.4% in the second quarter. Quest Partners LLC now owns 17,956 shares of the company’s stock valued at $147,000 after acquiring an additional 11,061 shares during the period. Finally, XTX Topco Ltd bought a new stake in shares of Cardlytics in the second quarter valued at approximately $107,000. 68.10% of the stock is owned by institutional investors.

Analysts Set New Price Targets

CDLX has been the topic of a number of research analyst reports. Bank of America downgraded shares of Cardlytics from a “neutral” rating to an “underperform” rating and lowered their price objective for the company from $4.00 to $3.50 in a research report on Thursday, August 15th. Lake Street Capital cut shares of Cardlytics from a “buy” rating to a “hold” rating and lowered their price target for the company from $18.00 to $5.00 in a report on Thursday, August 8th. Northland Capmk downgraded shares of Cardlytics from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 16th. Craig Hallum cut Cardlytics from a “buy” rating to a “hold” rating in a research report on Thursday, August 8th. Finally, Northland Securities lowered Cardlytics from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $7.00 to $5.00 in a research report on Friday, August 16th. One investment analyst has rated the stock with a sell rating and five have given a hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $7.50.

Get Our Latest Stock Analysis on CDLX

Cardlytics Company Profile

(Get Free Report)

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.

Featured Articles

Insider Buying and Selling by Quarter for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.